Posted On: 09/02/2014 9:27:46 AM
Post# of 30066
I don't know why you would be disappointed. Upfront money was never going to come from the CLIA partner. GC has to show that he's willing to go alone with Lympro to make BP step up if they really want to partner.
Your quote:
"I keep wondering why nobody is willing to pay for it if it is so good. Let's be realistic, a company with a net profit of +1B/year can afford paying 50, 100 or 150M for a first in class diagnostic test, so why it is not happening?"
How do you know nobody is willing to pay for it? Just because they haven't yet doesn't mean they won't or that negotiations aren't ongoing. Today is the first step in the commercialization process for Lympro. There is absolutely zero reason to be disappointed.
Your quote:
"I keep wondering why nobody is willing to pay for it if it is so good. Let's be realistic, a company with a net profit of +1B/year can afford paying 50, 100 or 150M for a first in class diagnostic test, so why it is not happening?"
How do you know nobody is willing to pay for it? Just because they haven't yet doesn't mean they won't or that negotiations aren't ongoing. Today is the first step in the commercialization process for Lympro. There is absolutely zero reason to be disappointed.
(0)
(0)
